BioCentury
ARTICLE | Clinical News

Keryx gains on Zerenex data in non-dialysis CKD patients

October 17, 2013 12:03 AM UTC

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) closed up $1.73 (20%) to $10.49 on Wednesday on the release of an abstract showing that Zerenex ferric citrate met the primary endpoint in a 90-patient Japanese Phase III trial to treat hyperphosphatemia in non-dialysis dependent patients with chronic kidney disease (CKD). Zerenex reduced mean serum phosphorus levels from baseline to week 12 vs. placebo (p<0.0001). The trial was funded by Keryx's Japanese partner Japan Tobacco Inc. (Tokyo:2914; Osaka:2914). The data are slated to be presented at the American Society of Nephrology meeting in November. Keryx also expects data in November from a Phase II trial evaluating Zerenex in anemic patients with stage III-V non-dialysis dependent CKD. ...